Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment resp
Gilead Sciences, Inc. $GILD Shares Bought by Allworth Financial LP
04:12am, Wednesday, 12'th Nov 2025
Allworth Financial LP boosted its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 10.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities an
Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript
02:41pm, Monday, 10'th Nov 2025
Gilead Sciences, Inc. ( GILD ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Presentation Unknown Analyst Good mo
AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit
04:00am, Monday, 10'th Nov 2025
LOS ANGELES--(BUSINESS WIRE)--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that w
Gilead's breast cancer drug fails to meet main goal of late-stage study
08:41am, Friday, 07'th Nov 2025
Gilead Sciences said on Friday its breast cancer drug Trodelvy failed to meet the main goal of a late-stage study.
Gilead Provides Update on Phase 3 ASCENT-07 Study
08:30am, Friday, 07'th Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a fi
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living w
3 Cash-Rich Stocks With High Growth Potential Right Now
06:36pm, Wednesday, 05'th Nov 2025
When it comes to long-term growth in the stock market, cash is king. In this article, we're specifically looking at free cash flow (FCF).
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
10:01am, Wednesday, 05'th Nov 2025
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Tuesday, 04'th Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Con
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
09:41am, Tuesday, 04'th Nov 2025
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
09:10am, Monday, 03'rd Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of He
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
01:41pm, Friday, 31'st Oct 2025
Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Friday, 31'st Oct 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
08:00am, Friday, 31'st Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo®
